Congress orders audit of federal biotech workforce—no new spending
H.R. 8930 — Federal Biotechnology Workforce Assessment Act · Filed by Ro Khanna (D-CA) · 2 cosponsors · Introduced May 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to conduct a comprehensive assessment of its biotechnology workforce across 14+ agencies, identifying current staffing levels, future needs over 5 and 10 years, required qualifications, security clearance gaps, and training opportunities. The Director of the Office of Personnel Management must report findings to Congress within 180 days, including recommendations for filling gaps through internal retraining, inter-agency transfers, temporary expert contracts, and public-private talent exchanges.
Why we flagged it
The bill is a straightforward administrative directive requiring federal workforce planning and reporting. It does not create new programs, spending, or regulatory authority—only a fact-finding and assessment mandate.
What the text implies
- The assessment may reveal significant federal biotechnology staffing shortages, potentially creating political pressure for future appropriations or hiring authority bills.
- Public-private talent exchange provisions could normalize temporary movement of federal employees to private biotech firms, raising potential conflicts of interest or IP ownership questions if not carefully managed.
The full analysis lists 4 implications of this text.
Who it affects
This is a straightforward government capacity-building measure that improves federal workforce planning in a critical sector (biotechnology) without imposing costs on citizens or creating private-sector carve-outs. Better federal biotechnology capacity serves the public interest by strengthening regulatory oversight, research, and national competitiveness.